Mark William Hocevar, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 28 | 2021 | 5709 | 1.300 |
Why?
|
| Hyperparathyroidism, Primary | 4 | 2024 | 164 | 1.020 |
Why?
|
| Skin Neoplasms | 21 | 2021 | 5864 | 0.990 |
Why?
|
| Parathyroidectomy | 4 | 2024 | 244 | 0.920 |
Why?
|
| Parathyroid Glands | 6 | 2024 | 522 | 0.760 |
Why?
|
| Choline | 5 | 2024 | 522 | 0.740 |
Why?
|
| Slovenia | 13 | 2020 | 22 | 0.590 |
Why?
|
| Sentinel Lymph Node Biopsy | 11 | 2020 | 737 | 0.570 |
Why?
|
| Lymph Nodes | 8 | 2021 | 3473 | 0.560 |
Why?
|
| Thyroid Neoplasms | 11 | 2021 | 2360 | 0.490 |
Why?
|
| Carotid Body Tumor | 1 | 2014 | 34 | 0.460 |
Why?
|
| Axilla | 4 | 2011 | 625 | 0.430 |
Why?
|
| Paraganglioma | 1 | 2014 | 143 | 0.420 |
Why?
|
| Technetium Tc 99m Sestamibi | 2 | 2024 | 184 | 0.400 |
Why?
|
| Lymphatic Metastasis | 15 | 2021 | 2916 | 0.390 |
Why?
|
| Germ-Line Mutation | 6 | 2019 | 1887 | 0.380 |
Why?
|
| S100 Proteins | 1 | 2011 | 217 | 0.360 |
Why?
|
| Genes, p16 | 3 | 2008 | 159 | 0.350 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2014 | 493 | 0.320 |
Why?
|
| Fluorine Radioisotopes | 3 | 2024 | 424 | 0.310 |
Why?
|
| Nerve Growth Factors | 1 | 2011 | 564 | 0.310 |
Why?
|
| Testicular Neoplasms | 1 | 2014 | 805 | 0.300 |
Why?
|
| Receptor, Cannabinoid, CB2 | 2 | 2018 | 49 | 0.300 |
Why?
|
| Parotid Neoplasms | 1 | 2009 | 158 | 0.300 |
Why?
|
| Neck Dissection | 5 | 2021 | 201 | 0.290 |
Why?
|
| Head and Neck Neoplasms | 2 | 2014 | 2931 | 0.290 |
Why?
|
| Genetic Predisposition to Disease | 12 | 2020 | 18065 | 0.280 |
Why?
|
| Ultrasonics | 2 | 2022 | 208 | 0.280 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 2 | 2017 | 53 | 0.280 |
Why?
|
| Breast Neoplasms | 14 | 2012 | 21187 | 0.270 |
Why?
|
| Sunburn | 2 | 2021 | 156 | 0.250 |
Why?
|
| Nevus, Blue | 1 | 2005 | 43 | 0.240 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2008 | 326 | 0.240 |
Why?
|
| Lymph Node Excision | 6 | 2020 | 1273 | 0.230 |
Why?
|
| Radiopharmaceuticals | 3 | 2024 | 2734 | 0.230 |
Why?
|
| Sewage | 1 | 2023 | 44 | 0.220 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2005 | 234 | 0.220 |
Why?
|
| Preoperative Care | 5 | 2020 | 2258 | 0.220 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2004 | 64 | 0.220 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2024 | 94 | 0.220 |
Why?
|
| Genes, BRCA2 | 3 | 2012 | 593 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 5 | 2019 | 710 | 0.210 |
Why?
|
| Ultrasonography, Mammary | 1 | 2005 | 241 | 0.210 |
Why?
|
| Genes, BRCA1 | 3 | 2012 | 756 | 0.210 |
Why?
|
| Hydrodynamics | 1 | 2023 | 167 | 0.200 |
Why?
|
| Fibroma | 1 | 2004 | 200 | 0.200 |
Why?
|
| Benzofurans | 2 | 2018 | 139 | 0.180 |
Why?
|
| Carcinoma, Lobular | 1 | 2005 | 480 | 0.180 |
Why?
|
| Sodium Chloride | 1 | 2022 | 584 | 0.170 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2020 | 103 | 0.170 |
Why?
|
| Video-Assisted Surgery | 1 | 2020 | 51 | 0.170 |
Why?
|
| Calcitonin | 1 | 2021 | 329 | 0.170 |
Why?
|
| Fuzzy Logic | 1 | 2019 | 58 | 0.160 |
Why?
|
| Malus | 1 | 2019 | 51 | 0.160 |
Why?
|
| Neck | 2 | 2021 | 736 | 0.160 |
Why?
|
| Positron-Emission Tomography | 2 | 2014 | 6673 | 0.150 |
Why?
|
| Neoplasm Metastasis | 6 | 2020 | 4926 | 0.150 |
Why?
|
| Extremities | 1 | 2024 | 870 | 0.150 |
Why?
|
| Middle Aged | 40 | 2024 | 223740 | 0.150 |
Why?
|
| Adult | 38 | 2024 | 223818 | 0.150 |
Why?
|
| Neoplasm Staging | 6 | 2020 | 11262 | 0.150 |
Why?
|
| Aged | 37 | 2024 | 171790 | 0.140 |
Why?
|
| Medication Errors | 1 | 2023 | 784 | 0.140 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2005 | 1093 | 0.140 |
Why?
|
| Operating Rooms | 1 | 2023 | 793 | 0.140 |
Why?
|
| Aged, 80 and over | 22 | 2021 | 59738 | 0.140 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2021 | 342 | 0.140 |
Why?
|
| Nomograms | 2 | 2010 | 236 | 0.140 |
Why?
|
| DNA Mutational Analysis | 5 | 2019 | 4123 | 0.140 |
Why?
|
| Adenoma, Oxyphilic | 2 | 2010 | 152 | 0.130 |
Why?
|
| Sunscreening Agents | 2 | 2021 | 139 | 0.130 |
Why?
|
| Nevus | 1 | 2017 | 205 | 0.130 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2017 | 286 | 0.120 |
Why?
|
| Humans | 66 | 2024 | 768887 | 0.120 |
Why?
|
| Female | 48 | 2024 | 397464 | 0.120 |
Why?
|
| Biopsy, Needle | 5 | 2020 | 1627 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2020 | 16051 | 0.120 |
Why?
|
| Prognosis | 9 | 2016 | 30044 | 0.120 |
Why?
|
| Nuclear Medicine | 1 | 2018 | 262 | 0.120 |
Why?
|
| Ovarian Neoplasms | 4 | 2019 | 4919 | 0.110 |
Why?
|
| BRCA2 Protein | 1 | 2019 | 803 | 0.110 |
Why?
|
| Telomere-Binding Proteins | 1 | 2014 | 122 | 0.110 |
Why?
|
| Male | 37 | 2024 | 365249 | 0.110 |
Why?
|
| Genetic Loci | 4 | 2020 | 2630 | 0.110 |
Why?
|
| Carcinoma, Papillary | 2 | 2009 | 793 | 0.110 |
Why?
|
| Carcinoma | 3 | 2010 | 2340 | 0.100 |
Why?
|
| Piperidines | 2 | 2018 | 1669 | 0.100 |
Why?
|
| Survival Analysis | 6 | 2020 | 10115 | 0.100 |
Why?
|
| Self-Examination | 1 | 2012 | 71 | 0.100 |
Why?
|
| Sarcoma | 1 | 2004 | 1806 | 0.100 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 1156 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 20776 | 0.100 |
Why?
|
| Prostate | 1 | 2020 | 1781 | 0.100 |
Why?
|
| Agriculture | 1 | 2012 | 187 | 0.090 |
Why?
|
| Cervical Plexus | 2 | 2008 | 16 | 0.090 |
Why?
|
| Paclitaxel | 1 | 2018 | 1735 | 0.090 |
Why?
|
| Adolescent | 15 | 2019 | 89247 | 0.090 |
Why?
|
| Anesthetics, Local | 2 | 2008 | 1004 | 0.090 |
Why?
|
| Nerve Block | 2 | 2008 | 716 | 0.090 |
Why?
|
| Potassium Iodide | 1 | 2010 | 13 | 0.090 |
Why?
|
| Endoscopy | 1 | 2020 | 1862 | 0.080 |
Why?
|
| Sensitivity and Specificity | 5 | 2011 | 14751 | 0.080 |
Why?
|
| Pesticides | 1 | 2012 | 298 | 0.080 |
Why?
|
| Microglia | 1 | 2018 | 1376 | 0.080 |
Why?
|
| Sunbathing | 1 | 2010 | 66 | 0.080 |
Why?
|
| Predictive Value of Tests | 7 | 2019 | 15471 | 0.080 |
Why?
|
| Thyroidectomy | 5 | 2021 | 914 | 0.080 |
Why?
|
| Mutation | 6 | 2019 | 30266 | 0.080 |
Why?
|
| Telomerase | 3 | 2014 | 753 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 9442 | 0.080 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2008 | 74 | 0.080 |
Why?
|
| Child | 9 | 2021 | 80969 | 0.080 |
Why?
|
| Thyroglobulin | 1 | 2008 | 111 | 0.080 |
Why?
|
| Disease Progression | 4 | 2020 | 13677 | 0.080 |
Why?
|
| Telomere | 1 | 2014 | 943 | 0.080 |
Why?
|
| Ultrasonography | 4 | 2011 | 6001 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 2181 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2011 | 1793 | 0.070 |
Why?
|
| Logistic Models | 3 | 2019 | 13317 | 0.070 |
Why?
|
| Genome-Wide Association Study | 5 | 2020 | 12798 | 0.070 |
Why?
|
| Fruit | 1 | 2012 | 1165 | 0.070 |
Why?
|
| ROC Curve | 3 | 2019 | 3629 | 0.070 |
Why?
|
| Europe | 4 | 2018 | 3441 | 0.070 |
Why?
|
| Exons | 2 | 2012 | 2395 | 0.070 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2006 | 40 | 0.070 |
Why?
|
| Likelihood Functions | 1 | 2010 | 993 | 0.070 |
Why?
|
| Physical Examination | 1 | 2012 | 1262 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 3438 | 0.070 |
Why?
|
| Radiotherapy Dosage | 2 | 2011 | 2920 | 0.070 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2008 | 249 | 0.060 |
Why?
|
| Risk Factors | 12 | 2019 | 74971 | 0.060 |
Why?
|
| Plant Leaves | 2 | 2019 | 153 | 0.060 |
Why?
|
| Retrospective Studies | 11 | 2024 | 81892 | 0.060 |
Why?
|
| Registries | 4 | 2020 | 8384 | 0.060 |
Why?
|
| Young Adult | 8 | 2019 | 60110 | 0.060 |
Why?
|
| Thyrotropin | 1 | 2008 | 834 | 0.060 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2005 | 59 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2008 | 566 | 0.060 |
Why?
|
| Genetic Testing | 4 | 2019 | 3590 | 0.060 |
Why?
|
| Hippocampus | 1 | 2017 | 3786 | 0.060 |
Why?
|
| Multivariate Analysis | 4 | 2011 | 12093 | 0.060 |
Why?
|
| Waste Disposal, Fluid | 1 | 2023 | 34 | 0.060 |
Why?
|
| Methane | 1 | 2023 | 44 | 0.060 |
Why?
|
| Anaerobiosis | 1 | 2023 | 140 | 0.060 |
Why?
|
| Syringes | 1 | 2023 | 58 | 0.050 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 2003 | 66 | 0.050 |
Why?
|
| Phenotype | 6 | 2020 | 16735 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2008 | 1195 | 0.050 |
Why?
|
| Education, Medical, Continuing | 1 | 2008 | 829 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2005 | 1132 | 0.050 |
Why?
|
| Genotype | 5 | 2020 | 13048 | 0.050 |
Why?
|
| Bioreactors | 1 | 2023 | 246 | 0.050 |
Why?
|
| Polymorphism, Genetic | 3 | 2006 | 4251 | 0.050 |
Why?
|
| Intraoperative Period | 3 | 2008 | 513 | 0.050 |
Why?
|
| Gene Frequency | 1 | 2008 | 3625 | 0.050 |
Why?
|
| Israel | 2 | 2014 | 726 | 0.050 |
Why?
|
| Transducers | 1 | 2022 | 245 | 0.050 |
Why?
|
| Acoustics | 1 | 2022 | 244 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 5443 | 0.050 |
Why?
|
| Area Under Curve | 2 | 2019 | 1645 | 0.040 |
Why?
|
| Heterozygote | 3 | 2019 | 2798 | 0.040 |
Why?
|
| RNA | 2 | 2014 | 2727 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2024 | 890 | 0.040 |
Why?
|
| Australia | 2 | 2014 | 1265 | 0.040 |
Why?
|
| Parathyroid Neoplasms | 2 | 2014 | 245 | 0.040 |
Why?
|
| Reproducibility of Results | 4 | 2011 | 20244 | 0.040 |
Why?
|
| Thigh | 1 | 2021 | 239 | 0.040 |
Why?
|
| Pigmentation | 1 | 2020 | 143 | 0.040 |
Why?
|
| Mediastinum | 1 | 2021 | 272 | 0.040 |
Why?
|
| Cognition | 1 | 2017 | 7080 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 11934 | 0.040 |
Why?
|
| Skin | 1 | 2012 | 4507 | 0.040 |
Why?
|
| Health Behavior | 1 | 2010 | 2649 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2016 | 8095 | 0.040 |
Why?
|
| Proteins | 1 | 2013 | 6011 | 0.040 |
Why?
|
| Breast Neoplasms, Male | 2 | 2011 | 212 | 0.040 |
Why?
|
| Calibration | 2 | 2012 | 823 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 4053 | 0.040 |
Why?
|
| Contrast Media | 1 | 2011 | 5334 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 4784 | 0.040 |
Why?
|
| Ultrasonography, Interventional | 1 | 2005 | 1524 | 0.040 |
Why?
|
| Alleles | 1 | 2008 | 6901 | 0.040 |
Why?
|
| Family Health | 2 | 2017 | 1255 | 0.040 |
Why?
|
| Cytological Techniques | 1 | 2019 | 218 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 11229 | 0.040 |
Why?
|
| Automation | 1 | 2019 | 589 | 0.030 |
Why?
|
| Biopsy | 1 | 2008 | 6805 | 0.030 |
Why?
|
| Histocytological Preparation Techniques | 2 | 2008 | 33 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2008 | 2350 | 0.030 |
Why?
|
| Biological Transport | 1 | 2021 | 2085 | 0.030 |
Why?
|
| Skull | 1 | 2021 | 830 | 0.030 |
Why?
|
| Water | 1 | 2022 | 1421 | 0.030 |
Why?
|
| Risk Assessment | 4 | 2016 | 24330 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 39394 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2017 | 8758 | 0.030 |
Why?
|
| Sodium Chloride, Dietary | 2 | 2010 | 301 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2020 | 1505 | 0.030 |
Why?
|
| Nevus, Pigmented | 1 | 2017 | 222 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2013 | 13054 | 0.030 |
Why?
|
| Curriculum | 1 | 2008 | 3782 | 0.030 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2018 | 607 | 0.030 |
Why?
|
| Bupivacaine | 2 | 2008 | 413 | 0.030 |
Why?
|
| Hyperalgesia | 1 | 2018 | 527 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2020 | 11119 | 0.030 |
Why?
|
| Organ Size | 1 | 2019 | 2268 | 0.030 |
Why?
|
| Random Allocation | 1 | 2018 | 2396 | 0.030 |
Why?
|
| Prospective Studies | 4 | 2021 | 54950 | 0.030 |
Why?
|
| Consensus | 1 | 2024 | 3214 | 0.030 |
Why?
|
| Probability | 1 | 2019 | 2483 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2015 | 438 | 0.030 |
Why?
|
| Internationality | 1 | 2019 | 1008 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2020 | 65485 | 0.030 |
Why?
|
| Social Conformity | 1 | 2012 | 39 | 0.030 |
Why?
|
| Incidence | 4 | 2016 | 21545 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2024 | 4356 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2014 | 453 | 0.030 |
Why?
|
| Zinc Fingers | 1 | 2014 | 577 | 0.020 |
Why?
|
| Ribonucleoproteins | 1 | 2014 | 359 | 0.020 |
Why?
|
| Neuralgia | 1 | 2018 | 622 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2020 | 1841 | 0.020 |
Why?
|
| Palpation | 1 | 2011 | 166 | 0.020 |
Why?
|
| Groin | 1 | 2011 | 106 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2017 | 1193 | 0.020 |
Why?
|
| Lymphatic Irradiation | 1 | 2011 | 115 | 0.020 |
Why?
|
| Prevalence | 1 | 2008 | 15875 | 0.020 |
Why?
|
| Case-Control Studies | 3 | 2015 | 22294 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2020 | 2885 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2014 | 1154 | 0.020 |
Why?
|
| Base Sequence | 2 | 2012 | 12430 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2016 | 41800 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2021 | 42684 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2020 | 2487 | 0.020 |
Why?
|
| Computers | 1 | 2012 | 592 | 0.020 |
Why?
|
| Time Factors | 2 | 2008 | 40266 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 6856 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2018 | 1970 | 0.020 |
Why?
|
| DNA Helicases | 1 | 2014 | 854 | 0.020 |
Why?
|
| Sunlight | 1 | 2010 | 337 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2012 | 643 | 0.020 |
Why?
|
| Pedigree | 1 | 2016 | 4545 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2013 | 1364 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2008 | 354 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 8200 | 0.020 |
Why?
|
| Memory | 1 | 2017 | 2210 | 0.020 |
Why?
|
| Neoplasms | 2 | 2024 | 22390 | 0.020 |
Why?
|
| Geography | 1 | 2009 | 654 | 0.020 |
Why?
|
| Leg | 1 | 2011 | 1089 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2008 | 570 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2014 | 4624 | 0.020 |
Why?
|
| Aging | 1 | 2005 | 8765 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 2931 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 1515 | 0.020 |
Why?
|
| Cicatrix | 1 | 2011 | 799 | 0.020 |
Why?
|
| United States | 3 | 2023 | 73180 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2017 | 9682 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 3836 | 0.020 |
Why?
|
| Lymphedema | 1 | 2011 | 526 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 7472 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 9564 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2008 | 1498 | 0.010 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2003 | 167 | 0.010 |
Why?
|
| Amyloid beta-Peptides | 1 | 2017 | 3912 | 0.010 |
Why?
|
| Age of Onset | 1 | 2011 | 3346 | 0.010 |
Why?
|
| Iodine | 1 | 2005 | 286 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2003 | 767 | 0.010 |
Why?
|
| Health Surveys | 1 | 2012 | 4055 | 0.010 |
Why?
|
| Family | 1 | 2012 | 3208 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2004 | 751 | 0.010 |
Why?
|
| Cause of Death | 1 | 2011 | 3721 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2014 | 8742 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2003 | 563 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2003 | 564 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 5520 | 0.010 |
Why?
|
| Internet | 1 | 2012 | 3112 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2008 | 2592 | 0.010 |
Why?
|
| Infant | 1 | 2021 | 36541 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2003 | 1998 | 0.010 |
Why?
|
| Inflammation | 1 | 2018 | 10869 | 0.010 |
Why?
|
| Self Report | 1 | 2010 | 3773 | 0.010 |
Why?
|
| Research Design | 1 | 2014 | 6213 | 0.010 |
Why?
|
| Software | 1 | 2012 | 4480 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 17629 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 18366 | 0.010 |
Why?
|
| Anxiety | 1 | 2012 | 4677 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2007 | 3585 | 0.010 |
Why?
|
| Temperature | 1 | 2003 | 2235 | 0.010 |
Why?
|
| Adenoma | 1 | 2007 | 2164 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 4593 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2005 | 6346 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2008 | 3967 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8559 | 0.010 |
Why?
|
| Animals | 2 | 2018 | 169408 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2007 | 3489 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 13020 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 6085 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2017 | 23652 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2007 | 12469 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2008 | 4859 | 0.010 |
Why?
|
| Algorithms | 1 | 2012 | 14199 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 26384 | 0.010 |
Why?
|
| Obesity | 1 | 2013 | 13087 | 0.010 |
Why?
|
| Mice | 1 | 2017 | 82074 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2004 | 8664 | 0.000 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 17174 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 9618 | 0.000 |
Why?
|